AU
UK
CA
US
IND
NZ
Last update at 2026-06-04T17:51:00Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
Q1 2025 Regenxbio Inc Earnings Call
Tue 13 May 25, 01:44 PMRegenxbio's Gene Therapy Outlook Dims As Rival Treatments Gain Ground, Goldman Sachs Warns
Tue 11 Feb 25, 08:20 PMJPMorgan Chase & Co. Reduces Stake in Regenxbio Inc
Thu 17 Oct 24, 07:04 PM7 Biotech Stocks to Buy for Their Game-Changing Potential
Thu 08 Aug 24, 10:00 AM| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -280.40500M | 141.25M | -106.01000M | -97.48800M | 104.12M |
| Minority interest | - | - | - | - | - |
| Net income | -280.32100M | 127.84M | -111.25000M | -94.73300M | 99.94M |
| Selling general administrative | 85.28M | 79.33M | 63.82M | 51.81M | 36.85M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | 58.18M | 418.51M | 118.85M | 26.99M | 208.87M |
| Reconciled depreciation | 12.91M | 9.56M | 8.41M | 7.15M | 3.98M |
| Ebit | -262.87600M | 159.98M | -119.23300M | -148.99800M | 77.05M |
| Ebitda | -262.53400M | 160.70M | -114.96200M | -197.55700M | 81.03M |
| Depreciation and amortization | 0.34M | 0.72M | 4.27M | -48.55900M | 3.98M |
| Non operating income net other | - | 7.54M | 13.99M | 51.51M | 16.02M |
| Operating income | -262.87600M | 159.98M | -119.23300M | -148.99800M | 88.10M |
| Other operating expenses | 375.60M | 310.37M | 273.80M | 184.23M | 130.41M |
| Interest expense | 23.25M | 26.28M | 0.77M | 107.22M | 0.00000M |
| Tax provision | -0.08400M | 13.41M | 5.24M | -2.75500M | 4.18M |
| Interest income | 0.34M | 0.72M | 4.27M | 2.95M | 8.95M |
| Net interest income | -22.91200M | -25.55800M | 3.50M | 2.95M | 8.95M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | -0.08400M | 13.41M | 5.24M | -2.75500M | 4.18M |
| Total revenue | 112.72M | 470.35M | 154.57M | 35.23M | 218.50M |
| Total operating expenses | 321.06M | 258.53M | 238.09M | 175.99M | 120.77M |
| Cost of revenue | 54.55M | 51.83M | 35.71M | 8.24M | 9.64M |
| Total other income expense net | -17.52900M | -18.73300M | 13.22M | 51.51M | 7.07M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | -280.32100M | 127.84M | -111.25000M | -94.73300M | 99.94M |
| Net income applicable to common shares | -280.32100M | 127.84M | -111.25000M | -94.73300M | 99.94M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 573.97M | 833.27M | 1113.90M | 708.16M | 497.91M |
| Intangible assets | - | - | - | - | - |
| Earning assets | - | - | - | - | - |
| Other current assets | 33.37M | 9.35M | 10.20M | 1.95M | 4.20M |
| Total liab | 262.23M | 317.07M | 349.61M | 330.41M | 47.71M |
| Total stockholder equity | 311.74M | 516.20M | 764.30M | 377.75M | 450.20M |
| Deferred long term liab | - | - | - | - | - |
| Other current liab | 100.27M | 95.39M | 114.00M | 67.88M | 21.51M |
| Common stock | 0.00400M | 0.00400M | 0.00400M | 0.00400M | 0.00400M |
| Capital stock | 0.00400M | 0.00400M | 0.00400M | 0.00400M | 0.00400M |
| Retained earnings | -705.04700M | -441.55300M | -161.23200M | -289.07200M | -177.82200M |
| Other liab | - | 97.84M | 134.21M | 178.81M | 5.16M |
| Good will | - | - | - | - | - |
| Other assets | - | 9.93M | 1113.90M | 8.78M | 10.04M |
| Cash | 34.52M | 96.95M | 345.21M | 338.43M | 69.51M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 130.27M | 130.43M | 130.47M | 81.45M | 33.68M |
| Current deferred revenue | 0.15M | 1.83M | 3.33M | 0.45M | 3.33M |
| Net debt | 54.77M | -2.15300M | -258.52800M | -265.77300M | -58.21900M |
| Short term debt | 7.07M | 6.00M | 1.75M | 2.50M | 2.42M |
| Short long term debt | - | - | - | - | - |
| Short long term debt total | 89.29M | 94.80M | 86.68M | 72.65M | 11.29M |
| Other stockholder equity | 1021.21M | 973.14M | 928.10M | 667.18M | 627.81M |
| Property plant equipment | - | 206.80M | 192.45M | 56.47M | 39.05M |
| Total current assets | 334.97M | 415.98M | 518.83M | 531.20M | 345.03M |
| Long term investments | 38.87M | 200.56M | 394.17M | 50.08M | 103.78M |
| Net tangible assets | - | 516.20M | 764.30M | 377.75M | 450.20M |
| Short term investments | 240.74M | 267.69M | 112.23M | 137.31M | 226.70M |
| Net receivables | 26.34M | 28.08M | 32.44M | 43.00M | 38.15M |
| Long term debt | - | - | - | - | - |
| Inventory | - | 13.90M | 18.75M | 10.51M | 6.47M |
| Accounts payable | 22.79M | 27.21M | 11.39M | 10.62M | 6.41M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | -4.42900M | -15.40100M | -2.56900M | -0.36000M | 0.20M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | 0.00400M | 0.00400M | 0.00400M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | -161.23200M | -289.07200M | -177.82200M |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 4.81M | 9.93M | 10.72M | 9.88M | 10.04M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 239.00M | 417.29M | 595.08M | 176.97M | 152.88M |
| Capital lease obligations | 89.29M | 94.80M | 86.68M | 72.65M | 11.29M |
| Long term debt total | - | - | - | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -11.92900M | -322.46700M | 147.34M | 105.28M | -266.08000M |
| Change to liabilities | 17.62M | -3.20300M | 20.05M | 7.29M | 9.05M |
| Total cashflows from investing activities | -11.92900M | -406.64200M | 122.76M | 93.56M | -279.35800M |
| Net borrowings | - | - | - | - | - |
| Total cash from financing activities | -28.84000M | 195.25M | 200.21M | 8.38M | 204.44M |
| Change to operating activities | -8.47000M | 29.30M | 20.24M | 2.37M | 5.31M |
| Net income | -280.32100M | 127.84M | -111.25000M | -94.73300M | 99.94M |
| Change in cash | -248.25700M | 7.48M | 268.91M | -5.77000M | 29.73M |
| Begin period cash flow | 347.24M | 339.76M | 70.84M | 76.61M | 46.88M |
| End period cash flow | 98.98M | 347.24M | 339.76M | 70.84M | 76.61M |
| Total cash from operating activities | -207.48800M | 218.88M | -54.06100M | -107.70500M | 104.65M |
| Issuance of capital stock | 0.00000M | 216.44M | 0.00000M | 0.00000M | 189.72M |
| Depreciation | 12.91M | 9.56M | 8.41M | 7.15M | 3.98M |
| Other cashflows from investing activities | - | - | 2.29M | 105.28M | -266.08000M |
| Dividends paid | - | - | - | - | - |
| Change to inventory | - | 29.30M | 17.85M | 2.37M | 5.35M |
| Change to account receivables | 4.82M | 14.12M | -9.89800M | -8.62200M | -16.80300M |
| Sale purchase of stock | 1.74M | 1.77M | 1.80M | 1.31M | 0.85M |
| Other cashflows from financing activities | -33.38600M | -22.95600M | 198.41M | 7.06M | 13.88M |
| Change to netincome | 45.95M | 41.25M | 40.56M | 21.13M | 16.66M |
| Capital expenditures | 30.72M | 84.17M | 26.87M | 11.72M | 13.28M |
| Change receivables | - | 14.12M | -9.89800M | -8.62200M | -16.80300M |
| Cash flows other operating | - | -1.25400M | -3.01300M | -38.72500M | -8.92800M |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | 7.48M | 268.91M | -5.77000M | 29.73M |
| Change in working capital | 13.98M | 40.22M | 14.22M | -5.32500M | -7.77400M |
| Stock based compensation | 40.79M | 38.81M | 31.95M | 26.85M | 16.64M |
| Other non cash items | 5.16M | 4.36M | -1.22900M | -2.68300M | -8.93200M |
| Free cash flow | -238.21200M | 134.70M | -80.93000M | -119.42500M | 91.37M |
Sector: Healthcare Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| RGNX Regenxbio Inc |
0.18 2.77% | 6.88 | - | - | 9.83 | 2.85 | 7.78 | -2.9303 |
| NVO Novo Nordisk A/S |
1.81 4.32% | 43.81 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| NONOF Novo Nordisk A/S |
1.78 4.23% | 44.00 | 41.06 | 31.25 | 2.08 | 33.11 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
12.68 2.96% | 441.01 | 29.67 | 24.33 | 10.38 | 5.83 | 9.33 | 20.00 |
| REGN Regeneron Pharmaceuticals Inc |
6.44 1.04% | 625.39 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.
9804 Medical Center Drive, Rockville, MD, United States, 20850
| Name | Title | Year Born |
|---|---|---|
| Mr. Kenneth T. Mills | Pres, CEO & Director | 1975 |
| Mr. Vittal K. Vasista | Exec. VP & Chief Financial Officer | 1968 |
| Mr. Curran M. Simpson M.S. | Exec. VP and Chief Operations & Technology Officer | 1962 |
| Dr. Olivier Danos Ph.D. | Exec. VP & Chief Scientific Officer | 1958 |
| Mr. Patrick J. Christmas II, J.D. | Exec. VP & Chief Legal Officer | 1971 |
| Ms. Tricia Truehart | VP of Investor Relations & Corp. Communications | NA |
| Mr. Andrew Yost | VP of Corp. Devel. | NA |
| Ms. Shiva G. Fritsch | Chief People Officer | NA |
| Dr. Laura A. Coruzzi J.D., Ph.D. | Sr. VP of Intellectual Property | 1953 |
| Dr. Ram Palanki Pharm.D. | Sr. VP of Commercial Strategy & Operations | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Please wait processing your request...